

EPIX Pharmaceuticals, Inc.  
Form 8-K  
July 13, 2006

Table of Contents

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549  
FORM 8-K  
CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934  
Date of report (Date of earliest event reported): July 13, 2006  
EPIX Pharmaceuticals, Inc.**

(Exact Name of Registrant as Specified in Its Charter)  
**Delaware**

(State or Other Jurisdiction of Incorporation)

**000-21863**

(Commission File Number)

**04-3030815**

(IRS Employer Identification No.)

**161 First Street, Cambridge, Massachusetts 02142**

(Address of Principal Executive Offices)

(Zip Code)

**(617) 250-6000**

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01. Other Events.

Item 9.01. Financial Statements and Exhibits.

**SIGNATURES**

Ex-99.1 Press Release dated July 13, 2006

---

**Table of Contents**

**Item 8.01. Other Events.**

On July 13, 2006, EPIX Pharmaceuticals, Inc. (the Company ) issued a press release announcing that Schering AG has decided not to exercise its option for the Company s fibrin-binding imaging agent EP-2104R. Under the terms of the Company s agreement with Schering AG, the Company will retain full rights to the EP-2104R program. The Company intends to pursue a collaboration for the continued development of EP-2104R with other potential partners. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) The following exhibits are furnished with this report:

Exhibit Number	Description
99.1	Press Release dated July 13, 2006

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EPIX Pharmaceuticals, Inc.  
(Registrant)

Date: July 13, 2006

/s/ Robert B. Pelletier

Robert B. Pelletier  
*Executive Director of Finance and  
Principal Accounting Officer*